Search clinical trials for: Refractory to standard of care

Total 491528 results

Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Taiwan, Spain, Korea, Republic of, Thailand, Italy, Malaysia, Turkey, Australia
ETH Zurich
University of Zurich

Not yet recruiting

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML (RAPID-01)

AML, Adult
Children's Hospital Medical Center, Cincinnati

Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Lymphoma | Follicular Lymphoma | Leukemia | B Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | AML | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | T-cell Lymphoma | Peripheral T Cell Lymphoma and other conditions

United States
Qurgen Inc.

Recruiting

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor

United States
Novartis Pharmaceuticals

Recruiting

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

Follicular Lymphoma (FL)

Australia, Korea, Republic of, Spain, Singapore, Poland, Taiwan, Hungary, Czechia, Romania, Slovakia
University of Birmingham
Cancer Research UK; Genmab

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United Kingdom
Stanford University
Kite Pharma

Recruiting

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Non-Hodgkin Lymphoma | Large B-cell Lymphoma

United States
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Rotator Cuff Tendinopathy

United States, Spain, Greece, Hungary, China, Italy, Thailand, Poland, Denmark
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Rotator Cuff Tendinopathy

United States, France, Turkey, Argentina, Chile, Portugal, United Kingdom, Czechia, Denmark, Malaysia, Canada, Bulgaria, Slovakia
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

Multiple Myeloma

Australia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
Faron Pharmaceuticals Ltd

Recruiting

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Relapsed/Refractory AML

United States, Finland
Kite, A Gilead Company

Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)

Relapsed/Refractory Follicular Lymphoma

United States, Spain, United Kingdom, Italy, France, Japan, Germany
Shanghai Zhongshan Hospital

Recruiting

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Colorectal Neoplasms Malignant

China
Fondazione Italiana Linfomi - ETS

Recruiting

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

Italy
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

Relapsed/Refractory Multiple Myeloma

Germany, Italy, Belgium, Spain, Netherlands, France, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B-Cell Lymphoma | DLBCL

Poland, United States, France, Israel, Italy, Turkey, Canada, Korea, Republic of, United Kingdom, Thailand, China
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Multiple Myeloma

United States, Spain, France, Greece
University Hospital Tuebingen
GlaxoSmithKline

Recruiting

Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)

Chronic Lymphoid Leukemia in Relapse

Germany
M.D. Anderson Cancer Center

Recruiting

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditions

United States
Cliniques universitaires Saint-Luc- Université...

Recruiting

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

Vascular Malformations

Germany, France, Belgium
Pfizer

Completed

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Multiple Myeloma

United States
Marinus Pharmaceuticals

Withdrawn

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Refractory Status Epilepticus

Spain, Switzerland, Germany, France, Austria, Italy, Belgium, United Kingdom, Czechia, Croatia, Finland, Lithuania, Israel, Hungary, Poland, Slovakia
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Kite, A Gilead Company

Active, not recruiting

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

United States, Spain, United Kingdom, Canada, Netherlands, Germany, France, Sweden, Israel, Switzerland, Belgium, Australia, Austria, Italy
Amgen

Terminated

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Italy, Belgium, Canada, Mexico, Germany, Korea, Republic of, United Kingdom, Taiwan, Australia, Spain, Austria, Israel, Czechia, Greece, Russian Federation, Poland, Turkey, Bulgaria, Ireland
M.D. Anderson Cancer Center
Patient-Centered Outcomes Research Institute

Withdrawn

Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)

Cardiac Arrhythmia | Cardiac | Ventricular Tachyarrhythmias

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Pfizer

Completed

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Multiple Myeloma

United States
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
Centre Hospitalier Universitaire de Nice

Completed

Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit (PROPOPAL1)

Refractory Pains | End of Life Patients

France
Celgene

Completed

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)

Lymphoma, Non-Hodgkin

United States, Belgium, Germany, Japan, Netherlands, France, Sweden, Italy, Spain, Switzerland, United Kingdom, Finland
Zambon SpA

Active, not recruiting

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) (BOSTON-2)

Bronchiolitis Obliterans | Lung Transplant Rejection | Lung Transplant; Complications | Lung Transplant Failure and Rejection | Chronic Rejection of Lung Transplant | Chronic Lung Allograft Dysfunction

France, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)

Relapsed/Refractory Multiple Myeloma

United States, Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
NanOlogy, LLC
US Biotest, Inc.

Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Cancer | Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Urinary Bladder Neoplasm | Cancer of the Bladder | Malignant Tumor of the Urinary Bladder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
VA Office of Research and Development

Completed

Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus (PRACTICE-DM)

Telemedicine

United States
Ohio State University Comprehensive Cancer Center

Completed

Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients

Acute Leukemia | Refractory Leukemia | Recurrent Leukemia

United States
Celgene

Active, not recruiting

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Multiple Myeloma

United States, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
Ann Marie Chikowski
Main Line Health

Completed

Optimizing Left Ventricular Lead To Improve Cardiac Output (CARE/VOLCANO)

Dilated Cardiomyopathy | Congestive Heart Failure | Ischemic Congestive Cardiomyopathy

United States
CSL Behring

Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Antibody-mediated Rejection

United States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
Roswell Park Cancer Institute
GlaxoSmithKline

Terminated

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Mesoblast, Inc.

Completed

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Versus Host Disease

United States, Italy, Australia, Canada, Switzerland, United Kingdom
University of Zurich
CytoSorbents Europe GmbH

Completed

Cytokine Adsorption in Severe, Refractory Septic Shock

Septic Shock | Cytokine Storm

Search clinical trials for: Refractory to standard of care

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations